Catalyx Taps Private 5G to Cut Line-Change Costs in Pharma Manufacturing

New updates have been reported about Catalyx.

Catalyx has entered a strategic partnership with Canoga Perkins to add deterministic private 5G Time Sensitive Networking to its OpenLine LineClearance Assistant 3.0, aiming to reduce reliance on wired infrastructure in life sciences manufacturing. The move is designed to cut installation time and cabling costs for pharmaceutical and other GMP-regulated production lines while maintaining stringent quality and compliance standards.

The 5G-enabled version of OpenLine LineClearance Assistant 3.0 is expected to eliminate most CAT6 cabling, requiring only local DC power at each camera and minimizing mechanical changes to existing equipment. Catalyx positions this as a way to accelerate line-clearance verification, ease deployment across multiple facilities, and address one of pharma’s most persistent bottlenecks: delays and errors during complex line changeovers.

From a cost and operational perspective, Catalyx anticipates that private 5G will deliver significant savings on installation labor, reduce downtime during upgrades, and simplify scaling of camera-based vision systems across large plants. The company also highlights real-time wireless verification as a lever to maintain uninterrupted production flow and GMP compliance, backed by ultra-reliable low-latency connectivity provided through Canoga Perkins’ SyncMetra 5G TSN solution.

Catalyx’s chief product and technology officer, Darin Cerny, said the 5G integration is a pivotal step in streamlining both deployment and ongoing operations of its AI-powered line-clearance platform. Canoga Perkins’ president, Malik Arshad, framed the collaboration as setting a new bar for flexibility and efficiency in pharmaceutical manufacturing by pairing TSN-based 5G with Catalyx’s machine vision and automation capabilities.

The partnership reinforces Catalyx’s broader strategy to deepen its footprint in life sciences by combining AI, machine vision, and advanced networking to reduce downtime and compliance risk in regulated environments. Catalyx plans to preview the 5G-enabled OpenLine LineClearance Assistant 3.0 at INTERPHEX New York from April 21–23, 2026, positioning the launch in front of a core audience of biopharma and device manufacturers evaluating next-generation production technologies.

With more than 30 years of experience and over 3,000 global projects delivered, Catalyx is effectively using this collaboration to differentiate its offering in a market increasingly focused on flexible, wireless, and data-rich production systems. For executives evaluating capital projects, the key implications are lower upfront infrastructure costs, faster deployment cycles, and a more modular approach to line-clearance automation that can be replicated across sites.

As life sciences manufacturers face pressure to shorten changeover times and increase throughput without compromising GMP compliance, Catalyx’s 5G-enabled solution targets a critical operational pain point. If adoption scales as intended, the partnership could shift industry expectations away from hard-wired, static inspection infrastructure toward more agile, software- and network-driven line-clearance models.

The integration of deterministic private 5G also positions Catalyx to layer on additional real-time capabilities over time, such as expanded analytics and multi-line coordination, leveraging the same wireless backbone. This could open future revenue streams in managed services and performance optimization, aligning with Catalyx’s existing professional services portfolio and its focus on long-term client relationships in highly regulated industries.